Payment overview · 2025
General Payments
$104.23
4 reported records · 4 companies
Healthcare provider profile · identity verified
Armando Roca, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · HOLLYWOOD, FL · NPI 1073511754
Verified facts
What the public records show
CMS Open Payments records show Armando Roca, D.O. received $104.23 in general payments during 2025 across 4 reported records.
Edwards Lifesciences Corporation accounted for 51.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 242 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $53.34 | 51.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.42 | 19.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.41 | 15.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.06 | 13.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $104.23 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.41 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.41 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 242 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
62 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
53 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
242 | 58 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
29 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 839 | 274 |
| Losartan Potassium | Losartan Potassium | 704 | 210 |
| Metformin Hcl | Metformin Hcl | 626 | 184 |
| Amlodipine Besylate | Amlodipine Besylate | 623 | 188 |
| Levothyroxine Sodium | Levothyroxine Sodium | 510 | 133 |
| Lisinopril | Lisinopril | 349 | 106 |
| Simvastatin | Simvastatin | 297 | 92 |
| Metoprolol Succinate | Metoprolol Succinate | 292 | 87 |
| Metoprolol Tartrate | Metoprolol Tartrate | 292 | 100 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 291 | 93 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 267 | 91 |
| Nifedipine Er | Nifedipine | 252 | 72 |
| Pantoprazole Sodium | Pantoprazole Sodium | 246 | 82 |
| Temazepam | Temazepam | 244 | 34 |
| Eliquis | Apixaban | 242 | 58 |
| Gabapentin | Gabapentin | 233 | 88 |
| Azithromycin | Azithromycin | 225 | 167 |
| Tamsulosin Hcl | Tamsulosin Hcl | 224 | 78 |
| Escitalopram Oxalate | Escitalopram Oxalate | 222 | 78 |
| Omeprazole | Omeprazole | 198 | 76 |
| Clopidogrel | Clopidogrel Bisulfate | 169 | 52 |
| Fluticasone Propionate | Fluticasone Propionate | 157 | 60 |
| Famotidine | Famotidine | 149 | 54 |
| Carvedilol | Carvedilol | 146 | 49 |
| Diclofenac Sodium | Diclofenac Sodium | 145 | 46 |
| Memantine Hcl | Memantine Hcl | 138 | 44 |
| Alprazolam | Alprazolam | 137 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 137 | 41 |
| Furosemide | Furosemide | 134 | 41 |
| Glimepiride | Glimepiride | 134 | 41 |
| Montelukast Sodium | Montelukast Sodium | 131 | 43 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 129 | 63 |
| Tizanidine Hcl | Tizanidine Hcl | 128 | 89 |
| Trazodone Hcl | Trazodone Hcl | 126 | 42 |
| Allopurinol | Allopurinol | 121 | 39 |
| Jardiance | Empagliflozin | 109 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 109 | 32 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 108 | 93 |
| Alendronate Sodium | Alendronate Sodium | 101 | 37 |
| Meclizine Hcl | Meclizine Hcl | 98 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 94 | 36 |
| Atenolol | Atenolol | 91 | 28 |
| Meloxicam | Meloxicam | 90 | 63 |
| Sildenafil Citrate | Sildenafil Citrate | 90 | 24 |
| Dicyclomine Hcl | Dicyclomine Hcl | 79 | 33 |
| Ketoconazole | Ketoconazole | 77 | 46 |
| Ozempic | Semaglutide | 75 | 14 |
| Potassium Chloride | Potassium Chloride | 73 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 71 | 23 |
| Glipizide | Glipizide | 70 | 21 |
| Lovastatin | Lovastatin | 70 | 20 |
| Finasteride | Finasteride | 69 | 24 |
| Clonazepam | Clonazepam | 68 | 17 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 68 | 30 |
| Buspirone Hcl | Buspirone Hcl | 67 | 22 |
| Glipizide Er | Glipizide | 63 | 18 |
| Farxiga | Dapagliflozin Propanediol | 62 | 15 |
| Metformin Hcl Er | Metformin Hcl | 62 | 22 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 62 | 52 |
| Methylprednisolone | Methylprednisolone | 61 | 48 |
| Azelastine Hcl | Azelastine Hcl | 56 | 29 |
| Donepezil Hcl | Donepezil Hcl | 55 | 22 |
| Mirtazapine | Mirtazapine | 55 | 17 |
| Mupirocin | Mupirocin | 55 | 32 |
| Tradjenta | Linagliptin | 54 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 54 | 41 |
| Symbicort | Budesonide/Formoterol Fumarate | 53 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 17 |
| Synthroid | Levothyroxine Sodium | 50 | 13 |
| Ezetimibe | Ezetimibe | 47 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | 18 |
| Spironolactone | Spironolactone | 46 | 17 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 45 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 44 | 11 |
| Irbesartan | Irbesartan | 44 | 15 |
| Latanoprost | Latanoprost | 44 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | 15 |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 42 | 16 |
| Bupropion Xl | Bupropion Hcl | 41 | 14 |
| Lorazepam | Lorazepam | 41 | 16 |
| Ramipril | Ramipril | 41 | suppressed |
| Celecoxib | Celecoxib | 39 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 38 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 37 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 36 | 14 |
| Ibuprofen | Ibuprofen | 36 | 22 |
| Bupropion Hcl Sr | Bupropion Hcl | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 35 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | 11 |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 33 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 33 | 13 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Levetiracetam | Levetiracetam | 29 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 29 | 28 |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Prednisone | Prednisone | 26 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | 12 |
| Naproxen | Naproxen | 22 | 18 |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Prolia | Denosumab | 21 | 12 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 19 | 18 |
| Ciclopirox | Ciclopirox | 19 | 11 |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 19 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 18 | 11 |
| Novolog | Insulin Aspart | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Brilinta | Ticagrelor | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 14 |
| Lactulose | Lactulose | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 12 |
| Dutasteride | Dutasteride | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Nadolol | Nadolol | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 11 |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Terconazole | Terconazole | 13 | 11 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | 11 |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $104.23 · 4 records | Edwards Lifesciences Corporation | AIRSUPRA, AREXVY, ELIQUIS, NURTEC ODT, SHINGRIX | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error